Last reviewed · How we verify
Placebo salve
Placebo salve is a Small molecule drug developed by Medical University of Graz. It is currently FDA-approved for Minor skin conditions and symptoms amenable to placebo response (e.g., mild itching, minor irritation).
A placebo salve produces therapeutic effects primarily through the placebo effect, where the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients.
A placebo salve produces therapeutic effects primarily through the placebo effect, where the expectation of treatment triggers physiological and psychological responses independent of active pharmacological ingredients. Used for Minor skin conditions and symptoms amenable to placebo response (e.g., mild itching, minor irritation).
At a glance
| Generic name | Placebo salve |
|---|---|
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Placebo salves contain inert ingredients with no known pharmacological activity. Their therapeutic benefit arises from the placebo effect—a well-documented phenomenon where patient expectation, conditioning, and the ritual of treatment activate endogenous healing mechanisms, including pain modulation, immune activation, and symptom relief. This is particularly effective for subjective symptoms such as pain, itching, and minor skin irritation.
Approved indications
- Minor skin conditions and symptoms amenable to placebo response (e.g., mild itching, minor irritation)
Common side effects
- Skin irritation from vehicle or excipients
- Allergic contact dermatitis
Key clinical trials
- Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (PHASE1)
- Nitroglycerin Ointment for Pain Relief After Endoscopic Hemorrhoid Band Ligation (PHASE4)
- A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis (PHASE2)
- Topical SGX302 for Mild-to-Moderate Psoriasis (PHASE2)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (PHASE3)
- Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial. (NA)
- A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis. (PHASE1)
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo salve CI brief — competitive landscape report
- Placebo salve updates RSS · CI watch RSS
- Medical University of Graz portfolio CI
Frequently asked questions about Placebo salve
What is Placebo salve?
How does Placebo salve work?
What is Placebo salve used for?
Who makes Placebo salve?
What development phase is Placebo salve in?
What are the side effects of Placebo salve?
Related
- Manufacturer: Medical University of Graz — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Minor skin conditions and symptoms amenable to placebo response (e.g., mild itching, minor irritation)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing